Catheter ablation versus no ablation for atrial fibrillation in cardiac amyloidosis: A propensity-matched cohort study
Global Cardiology Science and Practice · 29.06.2026 · 2026 (3)
DOI: 10.21542/gcsp.2026.26 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Global Cardiology Science and Practice, online erschienen am 29.06.2026. Verfasst von Joud Fahed und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Ascension Saint Agnes Hospital, Baltimore, Maryland, USA. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Atrial fibrillation (AF) is extremely common in cardiac amyloidosis (CA) due to amyloid infiltration and atrial electrical remodeling. We aim to compare ablation outcomes versus no-ablation in patients taking anti-arrhythmic drugs (AAD) in CA-associated AF.
Methods
Using TriNetX database (2019-2025), 5,562 patients with CA and AF were identified and divided into two groups: catheter ablation plus AADs (n=893) versus medical therapy alone (n=4,669). Baseline characteristics were adjusted and 1:1 propensity score matching was performed to account for baseline differences. Primary composite outcome included all-cause mortality, ischemic strokes, bleeding and subsequent myocardial infarction.
Results
870 patients were included in each cohort. At 12-month follow-up, catheter ablation was associated with a significantly lower risk of the composite outcome (8.3% vs 13.2%; HR 0.591, 95% CI 0.418–0.834, p=0.002), and reduced all-cause mortality. There were no significant differences in all-cause hospitalization, emergency department visits, new-onset heart failure, atrioventricular block, or cardiac arrest. Repeat ablation or cardioversion, and subsequent pacemaker or ICD implantation were more frequent in the ablation group.
Conclusion
Catheter ablation was associated with improved short-term outcomes despite higher arrhythmia recurrence. Ablation may be considered in carefully selected patients, particularly those with earlier-stage disease or significant symptoms.
Autor:innen und Institutionen
- Department of Medicine, Ascension Saint Agnes Hospital, Baltimore, Maryland, USA.
- Department of Hospital Medicine, Guthrie Cortland Regional Medical Center, Cortland, NY, USA.
- Advanced Cardiac Imaging Department, St. Francis Hospital and Heart Center, Roslyn, New York, USA.
- Department of Medicine, Foundation University Medical College, Islamabad 44000, Pakistan.
- Department of Medicine, Maimonides Medical Center, Brooklyn, New York, USA.
- Department of Medicine, Henry Ford, Warren, Michigan, USA.
Zitieren
APA
Fahed, J., Hamza, M., Naeem, A., Rab, A. U., Khan, M. H., Sheffeh, M. A., Basit, J., Assiri, S., & Alraies, M. C. (2026). Catheter ablation versus no ablation for atrial fibrillation in cardiac amyloidosis: A propensity-matched cohort study. Global Cardiology Science and Practice, 2026(3). https://doi.org/10.21542/gcsp.2026.26
Vancouver
Fahed J, Hamza M, Naeem A, Rab AU, Khan MH, Sheffeh MA, et al. Catheter ablation versus no ablation for atrial fibrillation in cardiac amyloidosis: A propensity-matched cohort study. Global Cardiology Science and Practice. 2026;2026(3). doi:10.21542/gcsp.2026.26
BibTeX
@article{Fahed2026,
author = {Fahed, Joud and Hamza, Mohammad and Naeem, Azka and Rab, Asad Ur and Khan, Muhammad Hashim and Sheffeh, Mohammad Ali and Basit, Jawad and Assiri, Salem and Alraies, M Chadi},
title = {Catheter ablation versus no ablation for atrial fibrillation in cardiac amyloidosis: A propensity-matched cohort study},
journal = {Global Cardiology Science and Practice},
year = {2026},
volume = {2026},
number = {3},
doi = {10.21542/gcsp.2026.26}
}
EUVIMED